The 1st Digital Pathology Software as Medical Device is Approved by TFDA Today JelloX “MetaLite DX Digital Pathology Software” just received TFDA approval. It is the first digital pathology product that can be used offline in Taiwan. CEO Yen-Yin Lin shares unique features of this product- a stand-alone design that can be easily installed on […]
JelloX Biotech Achieves A Major Milestone in Regulatory Approval Read More »
捷絡生技3D數位病理影像暨AI輔助診斷已成功應用於肺癌、前列腺癌、口腔癌病灶型態與分子標靶分析，並可整合傳統分子病理與多體學技術詳細分析病人檢體特徵，符合美國國家癌症中心(US National Cancer Institute)則公開徵求多尺度腫瘤觀測圖集(Multidimensional Tumor Atlases)相關發展倡議 >>原文連結
JelloX Biotech Leads Research in 3D Cancer Pathology as NCI Explores Potential Read More »
Taiwan-based start-up, JelloX Biotech, says its products will help doctors diagnose and treat cancer tumors with speed and accuracy without an added strain on budgets. The company made its debut at Intel Innovation in September. JelloX has gained the attention of healthcare experts and pharmaceutical brands for its potential for the future of cancer pathology using 3D
JelloX Biotech helps doctors diagnose and treat cancer tumors with speed and accuracy Read More »
The 1st 2022 Best Bio Startup CEO Award announced winners from 24 Taiwanese candidates on 3rd November 2022. Through three months of preparation, call for applications, proposal review, and an online poll of the audience’s favourable CEOs, 24 biomedical startup CEOs had finished their roadshows at the final. Irene Wang of Lin BioScience beat 24 other participants
Rise of next-generation biotech CEOs in Taiwan Read More »
SAN FRANCISCO, Nov. 8, 2022 /PRNewswire/ — JelloX Biotech’s debut at Intel® Innovation in September drew the attention of healthcare experts and pharmaceutical brands alike for the Taiwan-based startup’s potential to shape the future of cancer pathology using 3D imaging technology. JelloX’s products will help doctors diagnose and treat cancer tumors with greater speed and
JelloX Debut Highlights Potential to Disrupt Cancer Pathology Read More »
